(Q80087887)
Statements
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study (English)
George R Simon
Christopher R Garrett
Stephen C Olson
Michael Langevin
Irene A Eiseman
John J Mahany
Charles C Williams
Richard Lush
Adil Daud
Pamela Munster
Alberto Chiappori
Mayer Fishman
Gerold Bepler
Peter F Lenehan
Daniel M Sullivan